ArticleInternational journal of clinical oncology2025
Clinical implications of peripheral blood biomarkers in patients with advanced breast cancer treated with trastuzumab emtansine and trastuzumab deruxtecan.
Article in International journal of clinical oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Baseline peripheral blood immune markers associated with clinical outcomes in patients with advanced breast cancer treated with trastuzumab deruxtecan.BMC cancer · 2026Article
- Prognostic significance of peripheral myeloid-derived suppressor cells in advanced breast cancer.Breast cancer (Tokyo, Japan) · 2026Article
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
Abstract
backgroundDevelopment of antibody-drug conjugates, including trastuzumab emtansine (T-DM1) and trastuzumab deruxtecan (T-DXd), has improved the outcomes of patients with HER2-positive breast cancer. We compared the association between peripheral blood biomarkers and outcomes in patients with breast cancer treated with T-DM1 and T-DXd.
methodsEighty-five women treated with T-DM1 (n = 40) or T-DXd (n = 45) for advanced disease were evaluated. Overall survival (OS) and OS after the end of treatment (EOT) were compared based on changes in absolute lymphocyte count (ALC) and neutrophil-to-lymphocyte ratio (NLR) between baseline and EOT.
resultsIn the T-DM1 group, patients with a low NLR at EOT had significantly longer OS after EOT than those with a high NLR (p = 0.007), and patients with a high ALC at EOT had longer OS after EOT (p = 0.071). In the T-DXd group, the ALC and NLR were not associated with OS. The exploratory subgroup analysis suggested that patients with high ALC at EOT had better OS after EOT (p = 0.038) in the T-DXd (HER2-low) group (n = 19), whereas ALC and NLR were not associated with the outcome in the T-DXd (HER2-positive) group (n = 26). Multivariable analysis revealed that the NLR at EOT was an independent prognostic factor for OS after EOT, after adjusting for clinicopathological factors, in the T-DM1 group (p = 0.019).
conclusionImmune status may influence treatment outcomes in the T-DM1 and T-DXd (HER2-low) groups. Conversely, in the T-DXd (HER2-positive) group, the treatment outcome was independent of immune status.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.